Tailor-made heart simulation predicts the effect of cardiac resynchronization therapy in a canine model of heart

Nirmal Panthee1, Jun-ichi Okada2, Takumi Washio2

  • 1Department of Cardiac Surgery, School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 Japan.

Medical Image Analysis
|March 15, 2016
PubMed

Insights

Cardiac resynchronization therapy (CRT) simulations using patient-specific 3D heart models accurately predict treatment effectiveness. This approach helps optimize pacing lead placement for improved outcomes in heart failure patients.

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Computational Biology

Background:

  • Cardiac resynchronization therapy (CRT) is used for heart failure but has a 30% non-response rate.
  • Current selection criteria for CRT do not fully predict patient response.
  • Left bundle branch block (LBBB) is a common indication for CRT.

Purpose of the Study:

  • To evaluate the predictive capability of 3D heart model simulations for CRT response.
  • To determine if individualized electromechanical models can guide optimal lead placement.
  • To validate simulation predictions in a canine heart failure model.

Main Methods:

  • Created individualized 3D heart models from CT scans in 4 canine LBBB models.
  • Performed CRT simulations for 25 ventricular pacing lead positions.
  • Validated simulation predictions through acute pacing experiments.

Main Results:

  • Significant correlations found between simulated and observed ejection fraction (EF) improvements (P<0.01).
  • Simulations accurately predicted optimal and worst pacing lead positions.
  • Individualized models predicted hemodynamic improvements effectively.

Conclusions:

  • 3D heart model simulations can predict acute hemodynamic improvement from CRT.
  • This simulation approach aids in determining optimal pacing lead positioning.
  • Individualized modeling offers a promising tool to enhance CRT efficacy.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
743
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
537